Peter Lawson
Stock Analyst at Barclays
(2.00)
# 3,079
Out of 5,116 analysts
99
Total ratings
42.53%
Success rate
-9.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.30 | +3.29% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $100.11 | +0.89% | 1 | Oct 29, 2025 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $312.39 | +23.24% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $35.18 | +13.70% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $18.31 | +36.54% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $9.96 | -69.88% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $46.24 | -13.49% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.61 | +86.34% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.00 | +100.00% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $7.44 | +34.41% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.85 | +40.35% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $15.22 | -60.58% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $10.63 | +3.48% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $12.16 | +31.58% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $6.82 | +119.94% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $23.09 | -39.37% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.32 | +127.27% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.06 | +183.02% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.37 | +191.97% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $80.75 | -25.70% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $8.56 | +98.60% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $36.13 | +82.67% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $19.30 | +60.62% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $8.67 | +49.94% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.45 | +104.08% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.39 | -20.27% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $134.95 | +170.47% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $28.02 | +64.17% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $44.49 | +911.46% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.17 | +1,973.73% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $55.08 | -18.30% | 2 | Jan 23, 2018 |
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.30
Upside: +3.29%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $100.11
Upside: +0.89%
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $312.39
Upside: +23.24%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $35.18
Upside: +13.70%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $18.31
Upside: +36.54%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $9.96
Upside: -69.88%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $46.24
Upside: -13.49%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.61
Upside: +86.34%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.00
Upside: +100.00%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $7.44
Upside: +34.41%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.85
Upside: +40.35%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $15.22
Upside: -60.58%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $10.63
Upside: +3.48%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $12.16
Upside: +31.58%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $6.82
Upside: +119.94%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $23.09
Upside: -39.37%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.32
Upside: +127.27%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.06
Upside: +183.02%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.37
Upside: +191.97%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $80.75
Upside: -25.70%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $8.56
Upside: +98.60%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $36.13
Upside: +82.67%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $19.30
Upside: +60.62%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $8.67
Upside: +49.94%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.45
Upside: +104.08%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.39
Upside: -20.27%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $134.95
Upside: +170.47%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $28.02
Upside: +64.17%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $44.49
Upside: +911.46%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.17
Upside: +1,973.73%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $55.08
Upside: -18.30%